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Background: Meningococcal disease (MD) is a serious public
health concern, associated with high case fatality rates (10–20%)
and substantial morbidity. The objectives of this study were to
analyze epidemiological aspects of MD in the Federal District (FD),
Brazil, from 2000 to 2011 and to assess the impact of the meningo-
coccal serogroup C conjugate vaccine (MCCV).
Methods & Materials: Descriptive study of cases of MD among
residents of the FD. We included in the study conﬁrmed cases of
MD reported to the local surveillance. To reduce underreporting
we compared data to the Brazilian Mortality Database and the
Public Health Laboratory Database. We studied sociodemographic,
clinical, and pathogen-related variables. For the assessment of the
impact of MCCV, which was introduced in 2010 for children under
two, we compared the incidence of MD before and after vaccine
introduction in the recommended age groups for vaccination.
Results: We analyzed 490 conﬁrmed cases of MD in the period.
The strain B:4,7:P1.19,15 predominated before 2005 with 67.8%
(61/90) and the strains C:23:P1.14-6 with 40.9% (61/149) and
C:2a:P1.5, 2 with 12.8% (19/149) were more prevalent after 2005.
The average annual rates of incidence and mortality of MD in the
periodwere, respectively, 1.7 and0.4/100,000 inhabitants/year and
the average fatality rate was 21%. The incidence rate of MD was
higher in children under one year, ranging from 13.1 in 2011 to
38.7/100.000 inhabitants/year in 2000. Fatality rate was higher in
the group of 40 years old and more (40%) and among children with
two years old (32%). There was a statistically signiﬁcant reduction
(p-value =0.02) in the incidence of MD in children under two years
old from 21.3/100.000 inhabitants/year in 2009, to 6.6/100.000
inhabitants/year in 2011.
Conclusion: This study enabled us to verify the age groupsmost
affected by MD, the circulating phenotypes and to make a pre-
liminary assessment of the impact of conjugate vaccine against
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Background: According to the World Health Organisation
(WHO), South Africa (SA) is listed among the 22 high tuberculo-
sis (TB) burden countries. In 2011 SA reported 37,883 new cases
of childhood TB. The accuracy and completeness of this informa-
tion is doubtful due to the diagnostic challenges of paediatric TB
and poor surveillance mechanisms. This data potentially excludes
those children treated outside the National TB Programme (NTP)
facilities.
Outside the Private-Public Mix partnerships, the role of the pri-
vate sector in paediatric TB care is unknown.
Methods & Materials: A PubMed literature search (with an
appropriate search strategy), in-depth interviews with experts and
a review of a nationwide private hospital network hospitalizations
database was done to extract existing data about children treated
in non NTP facilities, broken down by age and disease type, and
understand the relative importance of these numbers compared to
the NTP ﬁgures. National Health Laboratories Coporate Dataware-
house data was also reviewed. The Private-Public Mix partners,e.g
mines,were excluded.
Results: The literature search yielded no speciﬁc data relating
to the treatment of children in the SA non-NTP facilities.
The experts interviewed, concurred that TB diagnosed in these
facilities was referred to NTPs for treatment. TB treatment is free
in the NTP. However,they noted that TB care in the private sector
was associated with diagnostic and treatment delays.
759 cases of TB were admitted into the private hospital net-
work during 2007–2012. 145were laboratory conﬁrmed PTB cases,
compared to 58 411 diagnosed in public sector laboratories. The
network has 28.4%market share of the private bed space,by extrap-
olation these cases represent 0.9% of conﬁrmed TB. 51% of these
were <5years old. 33% of all cases had non-respiratory disease. The
results exclude ambulatory patients.
ICD-10 Code <1 year (%) 1-4 years (%) 5-14 years (%) Total
Laboratory Conﬁrmed
Respiratory Tuberculosis
33(23) 41(28) 71(49) 145
Respiratory Tuberculosis not
Laboratory Conﬁrmed
86(24) 111(31) 163(45) 360
CNS Tuberculosis 28(27) 31(30) 45(43) 104
Other Organs 47(39) 25(21) 47(39) 119
Military TB 202(27) 214(29) 343(45) 759
Children with Tuberculosis diagnosed in the private hospital database (2007-2012).
Children with Tuberculosis diagnosed in the private hospital
database (2007–2012)
Conclusion: Little is known about the true burden of children
seeking TB care in the SA private sector outside the PPMmix, hence
there is a need to establish a surveillance system for these patients.
A once off survey to determine amount of paediatric TB beingman-
aged in the private sector is needed.
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Currently, there is no evidence of a system that ensures conti-
nuity of care and assesses treatment outcomes for these children.
http://dx.doi.org/10.1016/j.ijid.2014.03.1219
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Background: Yaws is a disﬁguring non-venereal treponemal
disease, one of the neglected tropical diseases continued to be
prevalent in isolated pockets in some of the tropical countries in
African, Asia andWestern Paciﬁc Regions of theWorldHealthOrga-
nization (WHO). It is a disease commonly seen amongmarginalized
poor section of the most neglected population. More than 50% of
the cases occur in children. Generally, it is said “yaws begins where
the road ends”.
Between 1952 and 1964, the WHO and the UNICEF embarked
on global treponema control campaigns to administer a single dose
long-acting benzathine penicillin to all yaws cases and their con-
tacts. About 50millionpeoplewere treated in46endemic countries
during the campaign. As a result, the burden the disease reduced by
more than 95 percent from 50 million to 2.5 million. Subsequently,
yaws lost its priority in the light of emerging other priority disease
control programmers and the goal of eradication was not reached.
Methods&Materials: The authors reviewed available informa-
tion on progress on yaws eradication and efﬁcacy of azithromycin
drug intervention to cure the disease.
One of the main objectives of the presentation is to advocate
global participants towards yaws disease to gain support to set a
momentum to achieve eradication by 2020.
Results: Though the extent of the endemicity is fully not known,
about 90 countries were believed to be endemic in the 1950s; 12
countries of them reported new yaws cases - 56 223 (2008) and 47
800 (2012) (WHO 2012).
Encouraged by the recent evidence of efﬁcacy of a single oral
dose of azithromycin in curing yaws disease in Papua New Guinea
and Ghana, WHO recommended single dose azithromycin-based
treatment strategy (Morges strategy 2012). Initially, a single dose
of azithromycin to entire yaws endemic community followed by
targeted treatment of cases and contacts.
Conclusion: Yaws endemic countries met in Geneva,
Switzerland in 2012 and 2013 and drafted operational guide-
lines to implement the new treatment strategy. Ghana, Papua New
Guinea, Solomon Islands and Vanuatu implemented pilot projects
to gain more experience in 2013.
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Background: Antimalarial drug resistance has emerged as one
of the greatest challenges facing malaria control today. It has
also been implicated in the spread of malaria to new areas and
re-emergence of malaria in areas where the disease had been erad-
icated. In this study, Prevalence andpreddiposing factors tomalaria
were determined.
Methods & Materials: Prevalence of falciparum malaria was
determined by microscopic examination of Giemsa-stained blood
samples of patients who presented with fever in selected State
Hospitals in Ogun State between 2008 and 2011.Structured Ques-
tionnaires were administered to patients or/and parents of infants
to determine the factors that could lead to the development of drug
resistance by the parasite in the study population.
Results: Out of 4066 subjects screened during the period of
study, 2550 (61.1%) were positive.Highest prevalence (72%) was
recorded in children 1-5 years while the same group also had
the highest parasitaemia of 1080. The study showed that 24.6%
of the patient visit hospitals for treatment, 12.0% use local heal-
ers while 25.0% buy antimalarial drugs without prescription. It
was also observed that some use more than one method in their
management of malaria. Those who combined antimalarial drugs
with traditional medicine from local healers were found to be
17.4%. Only 18% of the sample population used Insecticide treated
mosquito nets, 42.3% use window and door nets while 13% did not
employ any mosquito preventive method.
Conclusion: Continuous use of the current antimalarial drugs
increases the chance of resistance developing to those drugs. Con-
trol of drug use and reducing exposure of parasites to the drugs are
most effective where the parasite is still sensitive to the drug.
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